Comparing Oral Iron Supplementation Using Alternate-day Dosing to the Standard of Care Consecutive-day Dosing in Iron-depleted Women With or Without Mild Anemia: a Randomized Controlled Trial in the Philippines
试验速览
- 阶段
- 不适用
- 状态
- 终止
- 入组人数
- 22
- 试验地点
- 2
- 主要终点
- Event rate of GI side effects
研究概览
简要总结
Iron is very important for our body and performs vital tasks. Iron deficiency is a worldwide health problem. The prevalence of anemia in women of reproductive age in Southeast Asia is estimated to be 46.6% in 2019, with iron deficiency being one of the main reasons for anemia. There are different approaches to treat iron deficiency. One of them is the use of iron supplements. Recommended iron supplement treatments today often differ in dose, regimen and length. Experts recommend a dose of 80-200 mg of iron taken either daily or on several days per week, depending on the severity of the iron deficiency (with or without anemia). From certain guidelines lower amounts of iron are also recommended, as this could lead to fewer side effects.Previous studies have shown that both daily and multiple days per week administration can be effective in treating iron deficiency. Recently, several successive iron supplementation studies in Zurich showed that 24 h after ingestion of an oral dose of >60mg iron, the absorption of iron in the body is impaired. In addition it was measured that iron supplements taken only every other day instead of every day are absorbed about 30-50% better and have fewer side effects. Little is known about the long-term effect of this alternating regimen on iron status and side effects.With this 6-months study in the Philippines, the investigators want to compare two different supplementation regimens with oral iron to see if there is any difference in the iron status, intestinal inflammation levels, and side effects, and therefore if it would be better to take the iron supplements every 2 days instead of daily.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Double (Participant, Investigator)
盲法说明
Participants and investigators are blinded, double blind study.
入排标准
- 年龄范围
- 18 Years 至 45 Years(Adult)
- 性别
- Female
- 接受健康志愿者
- 是
入选标准
- •Female, 18 to 45 years old,
- •SF levels <25 µg/L,
- •Hb levels 11-15.5 g/dL
- •Normal Body Mass Index (18.5-25 kg/m2),
- •In possession of a mobile phone on which the study app can be loaded
- •Signed informed consent
排除标准
- •Elevated CRP > 5 mg/L
- •Any metabolic, gastrointestinal, kidney or chronic disease such as diabetes, renal failure, hepatic dysfunction, hepatitis, hypertension, cancer or cardiovascular diseases (according to the participants own statement) affecting iron metabolism,
- •Use of medication which may interfere with iron absorption, gut physiology and iron metabolism
- •Consumption of iron supplements within 2 weeks prior to study start and of additional iron supplements during the study period
- •Difficulties with blood sampling,
- •Known hypersensitivity or allergy to iron or placebo capsules in the given amount (ferrous sulfate, mannitol, silica)
- •Pregnancy, breastfeeding
- •Known or suspected non-compliance, drug or alcohol abuse
- •Cigarette smokers
结局指标
主要结局
Event rate of GI side effects
时间窗: Day 183
in alternate day group
Serum Ferritin (SF)
时间窗: Day 186
in alternate day group
次要结局
- Hepcidin(Day 183)
- Alpha-1-acid Glycoprotein (AGP)(Day 186)
- Intestinal Fatty Acid-binding Protein (I-FABP)(Day 183)
- Event rate of GI side effects(Day 183)
- Hemoglobin (Hb)(Day 183)
- Calprotectin(Day 183)
- Total iron binding capacity (TIBC)(Day 186)
- Serum Transferrin Receptor (sTfR)(Day 186)
- Severity of GI side effects(Day 183)
- Serum Ferritin (SF)(Day 186)
- Serum Iron (SFe)(Day 186)
- C-Reactive Protein (CRP)(Day 186)
- Incidence of GI side effects(Day 183)
- Event proportion of GI side effects(Day 183)
